Paragon Associates & Paragon Associates II Joint Venture Has $2.80 Million Stake in DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Paragon Associates & Paragon Associates II Joint Venture boosted its stake in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) by 6.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 514,784 shares of the company’s stock after acquiring an additional 32,170 shares during the quarter. DiaMedica Therapeutics accounts for about 6.5% of Paragon Associates & Paragon Associates II Joint Venture’s investment portfolio, making the stock its 6th largest holding. Paragon Associates & Paragon Associates II Joint Venture owned approximately 1.20% of DiaMedica Therapeutics worth $2,795,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of DiaMedica Therapeutics in the third quarter valued at about $40,000. LPL Financial LLC grew its stake in shares of DiaMedica Therapeutics by 8.2% in the fourth quarter. LPL Financial LLC now owns 152,000 shares of the company’s stock worth $825,000 after purchasing an additional 11,500 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in DiaMedica Therapeutics during the 4th quarter valued at about $81,000. Raymond James Financial Inc. bought a new position in DiaMedica Therapeutics during the 4th quarter valued at approximately $83,000. Finally, Blue Trust Inc. lifted its holdings in DiaMedica Therapeutics by 56.2% in the 4th quarter. Blue Trust Inc. now owns 69,122 shares of the company’s stock worth $375,000 after buying an additional 24,875 shares during the period. 10.12% of the stock is currently owned by institutional investors.

DiaMedica Therapeutics Trading Down 0.8 %

Shares of DMAC opened at $3.79 on Tuesday. DiaMedica Therapeutics Inc. has a 1-year low of $2.14 and a 1-year high of $6.82. The firm’s 50-day moving average price is $5.79 and its 200-day moving average price is $5.13. The firm has a market capitalization of $162.42 million, a price-to-earnings ratio of -6.77 and a beta of 1.52.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). On average, research analysts forecast that DiaMedica Therapeutics Inc. will post -0.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright boosted their target price on DiaMedica Therapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday, March 19th.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.